Search This Blog

Thursday, February 13, 2025

Trump Imposes Reciprocal Tariffs, Will Also Respond To Value Added Taxes

 As reported last night, Trump has officially signed an action on reciprocal tariffs, targeting all countries around the globe that have higher tariffs than the US. It appears that Trump has picked reciprocal in place of a inform tariff on all exports. That's just the start however: what is more important is that as we cautioned earlier, the US also appears set to retaliate against Europe's VAT buffer which could very well cripple the continent's exporters.

Here are the details, as BBG notes, the president signed a measure directing the US Trade Representative and Commerce secretary to propose new levies on a country-by-country basis in an effort to rebalance trade relations, a sweeping process that could take weeks or months to complete, leaving doubt as to when the tarifffs would take effect.

“I’ve decided, for purposes of fairness, that I will charge a reciprocal tariff, meaning whatever countries charge the United States of America,” Trump said in the Oval Office with Howard Lutnick standing by his side. “In almost all cases, they’re charging us vastly more than we charge them but those days are over.”

Fresh import taxes would be customized for each country, and will be meant to offset not just their own tariffs on US goods but also non-tariff barriers the nations impose in the form of unfair subsidies, regulations, value-added taxes, exchange rates and other factors that act to limit US trade, said an official, who briefed reporters before the announcement.

The VAT response is notable because as we noted last night, the tariff differential for the EU, for example, with and without VAT is massive and rises from just 2% (without VAT) to a whopping 18% with! And judging by Trump's comments, which said that the EU is "absolutely brutal" on trade, the inclusion of VAT is precisely meant to punish Europe.

As we discussed in greater depth last night, the chart below shows the amount that each country's VAT exceeds the US sales tax. And so, if indeed Trump imposes a reciprocal tariff policy also accounted for foreign VATs, it could add another 10% to the average US effective tariff rate.

Needless to say, that could be catastrophic to exporters, and Deutsche Bank's George Saravelos agrees writing that if reciprocal tariffs are applied on a VAT basis, "European countries would be much higher on the list of impacted countries given high consumption taxes." Like Goldman, the DB strategist notes that the overall US tariff rate would increase by more than 10% (figures below).

Reciprocal tariffs amount to Trump’s broadest action to address US trade deficits and what he characterizes as unfair treatment of American exports around the globe. Trump has already imposed 10% tariffs on Chinese goods and plans to slap 25% duties on all US steel and aluminum imports next month.

There's more: Trump told reporters that he would enact import taxes on cars, semiconductors and pharmaceuticals in addition to the reciprocal tariffs.

The text of Trump’s directive on tariffs was not immediately provided by the White House. Trump cited barriers in the EU, including a VAT, as an example of what the US is looking to respond to, while the official said Trump has also singled out Japan and South Korea as nations that he believes are taking advantage of the US, and thus could be targeted in his latest push.

The president said that he is hoping to have a discussion with other nations about how existing policies have created an imbalanced trade environment, the official said. And he’s more than happy to lower tariffs if countries want to pare their levies or remove other trade barriers, the official added.

Reciprocal tariffs are expected to hit hard in less-developed economies where average duties on US products are higher, according to Bloomberg Economics. It differs from a universal levy on all imports, as Trump proposed during the 2024 presidential campaign. The official said Trump could divert back to a global tariff strategy later on.

Trump announced his move just hours before he was set to host Indian Prime Minister Narendra Modi, whose country stands to be affected by reciprocal tariffs more than many other major trading partners. Trump has repeatedly criticized India’s its high tariff barriers.

According to Bloomberg, "Trump’s brinkmanship has injected uncertainty into the global economy, with businesses and consumers waiting to see how Trump proceeds on decision that could disrupt the US’s trade relationships with the rest of the world." According to others, Trump is merely responding to a world where all countries have higher tariffs than the US!

 https://www.zerohedge.com/markets/trump-imposes-reciprocal-tariffs-will-also-respond-value-added-taxes

IDEAYA, Gilead Plan More Collaboration on Trodelvy, IDE397 in Lung Cancer

 

  • Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC
  • The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors
  • MTAP-deletion prevalence in NSCLC is estimated to be approximately 15%

Pliant Next Steps After DSMB Recommendation on Phase 2b/3 in Idiopathic Pulmonary Fibrosis

 Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial’s independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). The panel, consisting of world-renowned experts in pulmonary diseases and biostatistics, will provide an independent recommendation to Pliant regarding the BEACON-IPF trial. Subsequently, the panel will serve as part of an expanded DSMB with the goal to reach a consensus recommendation regarding BEACON-IPF. The decision to assemble the outside panel was taken as the Company has not been able, through review of blinded data, to determine the rationale for the DSMB’s recommendation to pause enrollment and dosing in the trial. The Company expects this process to conclude in two to four weeks.

Following the DSMB’s previously announced recommendation, Pliant voluntarily paused enrollment and dosing in the BEACON-IPF clinical trial. Pliant is committed to remaining blinded ensuring the data integrity of the BEACON-IPF 2b clinical trial with the goal of maintaining its potential to serve as a registrational trial.

https://www.globenewswire.com/news-release/2025/02/13/3025849/0/en/Pliant-Therapeutics-Announces-Next-Steps-Following-DSMB-Recommendation-on-BEACON-IPF-a-Phase-2b-3-Trial-in-Patients-with-Idiopathic-Pulmonary-Fibrosis.html

Pfizer TALZENNA-XTANDI combo ups Survival in Metastatic Castration Resistant Prostate Cancer

 

  • TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status
  • TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1) and by 14 months in patients selected for HRR mutations (Cohort 2) versus standard of care XTANDI

Astrazeneca upped to Buy by UBS

 from Neutral

https://finviz.com/quote.ashx?t=AZN&ty=c&ta=1&p=d

Agios Encouraging Data From Rare Blood Disorder Study In Younger Patients

 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused achieved its primary endpoint of hemoglobin response.

Pyruvate kinase (PK) deficiency is a rare, inherited disorder that affects red blood cells.

The safety results were consistent with the safety profile for mitapivat previously observed for adult patients with PK deficiency who are not regularly transfused.

The study’s primary endpoint was hemoglobin response, defined as a ≥1.5 g/dL ​increase in hemoglobin concentration from baseline ​ sustained at two or more scheduled assessments at​ Weeks 12, 16, and 20.

In August 2024, Agios reported topline results from the ACTIVATE-KidsT Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are regularly transfused.

Based on the clinically meaningful results observed in both the ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies, Agios intends to submit a marketing application for mitapivat in pediatric patients with PK deficiency.

Concurrently, the company reported fourth-quarter Pyrukynd revenues of $10.7 million, up 20% sequentially, beating the consensus of $9.33 million. 223 unique patients have completed prescription enrollment forms, up 6% sequentially.

A total of 130 patients are on PYRUKYND therapy, inclusive of new prescriptions and continued therapy.


https://finance.yahoo.com/news/agios-pharmaceuticals-reveals-encouraging-data-174559629.html

Bezos' Blue Origin Reportedly Plans 10% Cut Of Workforce As SpaceX Dominates Space Race

 About a month after Blue Origin successfully launched its long-delayed flagship rocket from Cape Canaveral, Florida, the Jeff Bezos-backed rocket company reportedly prepares for its first round of layoffs. The move comes as Elon Musk's SpaceX continues dominating the commercial space industry, raising questions about how far Blue Origin has fallen behind in the global space race. 

Bloomberg reports that Blue Origin CEO Dave Limp held an all-hands employee meeting on Thursday morning to address new cost-cutting measures, including terminating about 10% of the workforce. The report was based on insiders at the meeting. 

According to Bloomberg, Blue Origin has about 14,000 employees on payroll across its headquarters in Seattle and operation sites in Florida, Texas, and Alabama. The 10% cut would equate to about 1,400 employees and focus on "thinning out layers" of management.

On Jan. 16, Blue Origin's New Glenn launched from Cape Canaveral, placing the company's Blue Ring Pathfinder test satellite into orbit. 

However, the rocket's reusable first-stage booster failed to land on a barge in the Atlantic Ocean, something SpaceX's reusable booster rockets do weekly, blasting Starlink satellites into orbit. 

Last August, Bloomberg noted that testing included a "factory mishap that damaged a portion of a future New Glenn rocket," adding the rocket company has "grappled with development delays, a sluggish corporate culture and explosive setbacks." 

Bezos and Musk have had a rocket-size competition. Who has the bigger rocket?

Source: FT

As previously noted, SpaceX leads the global rocket race, launching 86% of all upmass to space in the third quarter of 2024. Also, SpaceX's Starlink is dominating the global space internet race. 

https://www.zerohedge.com/technology/jeff-bezos-blue-origin-reportedly-plans-10-cut-workforce-spacex-dominates-space-race